Interestingly and highly relevant to the present study are the outcomes from a population-based case–control study which reported that aspirin users showed a ~37% reduction in the risk of developing TMPRSS2-ERG-positive PCa, and that the risk reduction was stronger with a longer duration of aspirin use [2]. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.